Bronchopulmonary dysplasia and corticosteroid therapy: a case review.
The use of corticosteroids as a treatment for chronic lung disease is increasing in newborn intensive care units. The anti-inflammatory mechanism of steroids suppresses the pulmonary inflammatory response, leading to improved pulmonary compliance and often a successful extubation. However, side effects, including sepsis, hypertension, glucosuria, and heme positive stools, have been reported. Caregivers must appreciate the multisystem biochemical effects of corticosteroids and anticipate the potential side effects when administering this medication. The article reviews the biochemical processes of dexamethasone, a synthetic corticosteroid, and presents a case study of an infant receiving dexamethasone. A question-and-answer format is interpolated throughout the case study and is intended to challenge the reader's knowledge of the pathophysiology of chronic lung disease and the biochemical actions of corticosteroids. Implications for nursing assessment and management of infants receiving this medication are reviewed.
Doyle
P
P
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001997:Bronchopulmonary Dysplasia / Q000188:drug therapy* / Q000451:nursing; D003907:Dexamethasone / Q000627:therapeutic use*; D016903:Drug Monitoring; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D017283:Neonatal Nursing; D010347:Patient Care Planning
D000893:Anti-Inflammatory Agents; D003907:Dexamethasone